Find recruiting clinical trials for bowel cancer (colorectal cancer) in the UK — including immunotherapy for MSI-H tumours, KRAS G12C inhibitors, novel antibody-drug conjugates, and AI-assisted screening innovations. See your treatment pathway and where trials fit in.
Free to use — Live data from ClinicalTrials.gov — Updated hourly
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Cancer confined to the bowel wall
Standard: Surgical resection, possible adjuvant chemotherapy for high-risk stage II (capecitabine, FOLFOX)
Lymph node involvement, higher risk of recurrence
Standard: Surgery + adjuvant FOLFOX or CAPOX for 3–6 months, radiotherapy (rectal cancer-specific)
Distant spread — most commonly to liver or lung
Standard: FOLFOX or FOLFIRI + bevacizumab (or cetuximab/panitumumab for RAS wild-type), pembrolizumab for MSI-H
Progression after multiple lines of therapy
Standard: TAS-102, regorafenib, rechallenge with prior agents; KRAS G12C inhibitors for biomarker-selected patients
Pembrolizumab has transformed treatment for mismatch repair-deficient (MSI-H) bowel cancer. Trials now test combinations with nivolumab + ipilimumab, and checkpoint inhibitors in earlier-stage MSI-H disease.
Sotorasib and adagrasib are oral targeted therapies for the KRAS G12C mutation (present in ~4% of bowel cancers). Trials combine these with EGFR inhibitors to overcome resistance pathways.
Novel ADCs targeting CEACAM5, HER2, and Trop-2 are being tested in biomarker-enriched bowel cancer trials. Enfortumab vedotin and trastuzumab deruxtecan are among the candidates in UK studies.
Trials for patients with liver-only metastases include perioperative chemotherapy regimens, radioembolisation (SIRT), stereotactic ablative radiotherapy (SABR), and strategies to increase resectability.
Loading trials from ClinicalTrials.gov...
The terms are used interchangeably. Bowel cancer (or colorectal cancer) includes both colon cancer and rectal cancer. They are often grouped together because their treatments are similar, though rectal cancer may involve radiotherapy more frequently.
Yes. MSI-H tumours (about 15% of bowel cancers) respond particularly well to immunotherapy. Pembrolizumab is now NICE-approved for first-line, and trials are testing combinations with other checkpoint inhibitors and novel agents.
Yes. Trials for later-line treatment include targeted therapies for RAS/BRAF wild-type tumours (cetuximab, panitumumab combinations), TAS-102 (trifluridine/tipiracil), regorafenib, and novel antibody-drug conjugates.
The NHS offers FIT (faecal immunochemical test) screening every 2 years for adults aged 60-74. Trials are testing improved screening methods, including multi-cancer early detection blood tests and AI-assisted colonoscopy.
Use our search above to find trials matching your condition and location. Review eligibility criteria carefully.
Talk to your GP or oncologist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.